Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for ulcerative colitis comprising mizoribine

A technology of ulcerative colitis and mizoribine, applied in the field of ulcerative colitis therapeutic medicine

Active Publication Date: 2012-11-28
ASAHI KASEI MEDICAL CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in one case of a child with ulcerative colitis, administration of mizoribine was discontinued due to oral reports of fever after the start of administration of mizoribine (Non-Patent Document 7)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for ulcerative colitis comprising mizoribine
  • Therapeutic agent for ulcerative colitis comprising mizoribine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] (1) Target patients

[0058] Four patients with ulcerative colitis (UC, ulcerative colitis) at the hospital to which the present inventor belongs (Oita Red Cross Hospital, hereinafter the same) were studied. Case numbers 1 to 4 were patients with a history of side effects caused by oral administration of 6-MP or azathioprine for ulcerative colitis of moderate severity or higher in the severity classification of the Ministry of Health, Labor and Welfare. Hereinafter, the ulcerative colitis patients targeted in Comparative Example 1 and Comparative Example 2 also had the same drug history.

[0059] (2) The determination method of the highest plasma concentration of mizoribine

[0060] The determination of the maximum plasma concentration of mizoribine was carried out according to the usual method (JChromatogr. 1988 Nov 18; 432: 340-5). After oral administration of mizoribine to the patient, 2 to 4 hours after the highest blood concentration can be obtained, collect 2ml ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a therapeutic agent for ulcerative colitis, which comprises mizoribine, has a therapeutic effect on ulcerative colitis, does not have concerns about the occurrence of an adverse side effect during the maintenance of remission of ulcerative colitis, and can be administered for a long period. Specifically disclosed is a therapeutic agent for ulcerative colitis, which comprises mizoribine. The therapeutic agent can be used for an ulcerative colitis patient who has received a leukocytapheresis therapy and is not administered with any immunosuppression agent other than mizoribine at least after the leukocytapheresis therapy is started. The administration of therapeutic agent to the patient is started at a point of time which lies during the application of the leukocytapheresis therapy and after the clinical condition of the patient is ameliorated. The therapeutic agent is administered to the patient at least once a day so that the maximum blood mizoribine level in the patient becomes not lower than 0.6 [mu]g / ml and lower than 1.5 [mu]g / ml.

Description

technical field [0001] The invention relates to a medicine for treating ulcerative colitis containing mizoribine. In particular, it relates to a therapeutic agent for ulcerative colitis containing mizoribine used in combination with leukapheresis. Background technique [0002] Among inflammatory bowel diseases, ulcerative colitis and Crohn's disease are chronic inflammatory diseases in which erosions or ulcers are formed in the intestinal mucosa, and there is a remission period in which symptoms are relieved and an active period in which diarrhea and bloody stools occur frequently. Symptoms are diseases whose number of patients increases year by year. It is estimated that about 100,000 people in Japan and about 1 million people in the United States are affected. The causes of these diseases are speculated to be bacterial or viral infections, genetic factors, disorders of blood vessels or lymphatic vessels of the digestive tract, etc., but the true cause is still unknown. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07H19/052A61K31/7056A61P1/04
CPCA61K31/7056A61P1/04A61P7/00
Inventor 石田哲也
Owner ASAHI KASEI MEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com